Lexeo Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$87.3MTTM through 30 Jun 2026
Free Cash Flow -$88.7MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-37.8%ROE
-35.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio13.89x
Net Debt-$227.6Mnet cash position
Cash & Equivalents$92.8M
Quality Metrics
Altman Z-Score7.48
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2022: $654K
Diluted EPS-$0.88TTMFY2025: $-1.86
Dividend
No dividend
Capital Allocation
R&D Spend$66.6M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Genetic Medicine Pipeline | $0 | View detailsSUNRISE-FA 2 pivotal trial initiation for LX2006 expected in Q2 2026; high-dose 12-month data update for LX2020 expected in Q4 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.